

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Adams Heather</u> (Last) (First) (Middle) <u>C/O BIONANO GENOMICS, INC.</u> <u>9540 TOWNE CENTRE DRIVE, SUITE</u> <u>100</u> (Street) <u>SAN DIEGO CA 92121</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/18/2020</u>	3. Issuer Name and Ticker or Trading Symbol <u>Bionano Genomics, Inc [BNGO]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Administrative Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>2,625</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>05/01/2027</u>	<u>Common Stock</u>	<u>116</u>	<u>1.3</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>05/01/2027</u>	<u>Common Stock</u>	<u>3,738</u>	<u>1.3</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(2)</u>	<u>09/30/2028</u>	<u>Common Stock</u>	<u>41,410</u>	<u>7.77</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(3)</u>	<u>02/28/2029</u>	<u>Common Stock</u>	<u>30,000</u>	<u>4.25</u>	<u>D</u>

Explanation of Responses:

- 25% of the shares vested on April 3, 2018, and the remaining shares vest in 12 equal quarterly installments thereafter.
- 25% of the shares vested on October 1, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.
- The shares vest in 48 equal monthly installments from March 1, 2019 (the "Grant Date").

Remarks:

Heather Adams02/20/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.